ENO1 and myelodysplastic syndrome: Although loss of heterozygosity of chromosome 1p has been associated with progression of MDS to AML, this has been mapped to involve regions distal to 1p36.3 and therefore less likely to involve ENO1 [33], negating the potential of this therapeutic strategy.